Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968880 | 1.00 | NFE2L2 (0.48) | NFE2L2ALDH1A1LMNAL3MBTL1CES2 | |
| SCHEMBL2924111 | 1.00 | NFE2L2 (0.48) | NFE2L2ALDH1A1LMNAL3MBTL1CES2 | |
| Hydrochloric Acid SCHEMBL28115149 | 0.98 | NFE2L2 (0.47) | NFE2L2ALDH1A1LMNAL3MBTL1CES2 | |
| SCHEMBL2928249 | 0.83 | GRIN2D (0.61) | NFE2L2ALDH1A1LMNAL3MBTL1CES2 | |
| SCHEMBL29775672 | 0.83 | GRIN2D (0.61) | NFE2L2ALDH1A1LMNAL3MBTL1CES2 | |
| SCHEMBL1931856 | 0.83 | GRIN2D (0.61) | NFE2L2ALDH1A1LMNAL3MBTL1CES2 | |
| SCHEMBL1931859 | 0.83 | GRIN2D (0.61) | NFE2L2ALDH1A1LMNAL3MBTL1CES2 | |
| SCHEMBL24885801 | 0.81 | LMNA (0.39) | NFE2L2ALDH1A1LMNAL3MBTL1USP2 | |
| SCHEMBL5676565 | 0.81 | HPGD (0.53) | NFE2L2ALDH1A1LMNAL3MBTL1GRIN2D | |
| SCHEMBL2774494 | 0.81 | MAPT (0.55) | ALDH1A1LMNAL3MBTL1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110845486-B | Triazole alcohol derivative and preparation method and application thereof | 中国人民解放军第二军医大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-110845486-A | Triazole alcohol derivative and preparation method and application thereof | 中国人民解放军第二军医大学 | 2020-02-28 | — | — | CN | disclosed |
| CN-106336383-B | A kind of trinitrogenazole alcohol analog derivative and its preparation method and application | 中国人民解放军第二军医大学 | 2019-05-14 | — | — | CN | disclosed |
| CN-106336383-A | Triazole alcohol derivative and preparation method and application thereof | 中国人民解放军第二军医大学 | 2017-01-18 | — | — | CN | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8846719-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| WO-2006064484-A1 | AZABICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-6887905-B2 | Treatment of depression or generalized anxiety disorder | PFIZER INC (US) | 2005-05-03 | — | — | US | disclosed |
| US-20030181458-A1 | Azabicyclic 5HT1 receptor ligands | PFIZER INC. | 2003-09-25 | — | — | US | disclosed |
| EP-1070065-B1 | AZABICYCLIC 5HT1 RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | disclosed |
| CN-1117092-C | Azabicyclo compounds, pharmaceutical compositions and medical uses thereof | PFIZER PROD INC (US) | 2003-08-06 | — | — | CN | disclosed |
| US-6525048-B1 | Aminomethylphenoxymethyl/benzisoxazole substituted azabicyclic compounds; depression, generalized anxiety disorder, obesity, migraine; 2-(5-Fluoro-benzo(d)isoxazol-3-y)-7-(3-morpholin-4-ylmethylphenoxymethyl) -octahydro-pyrido(1,2-a)pyrazine; | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| CN-1305477-A | Azablicyclic 5-HT, receptor ligands | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
| EP-1070065-A1 | AZABICYCLIC 5HT1 RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052907-A1 | AZABICYCLIC 5HT1 RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | NFE2L2 2986/4885ALDH1A1 938/4885LMNA 3918/4885 |
| US-20030181458-A1 | Azabicyclic 5HT1 receptor ligands | HTR1A, HTR1B, HTR1D | NFE2L2 4188/4885ALDH1A1 285/4885LMNA 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.